Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?

Detalles Bibliográficos
Autores principales: Zandi, Milad, Behboudi, Emad, Soltani, Saber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312046/
https://www.ncbi.nlm.nih.gov/pubmed/34325045
http://dx.doi.org/10.1016/j.ijid.2021.07.053
_version_ 1783729072591863808
author Zandi, Milad
Behboudi, Emad
Soltani, Saber
author_facet Zandi, Milad
Behboudi, Emad
Soltani, Saber
author_sort Zandi, Milad
collection PubMed
description
format Online
Article
Text
id pubmed-8312046
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-83120462021-07-26 Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins? Zandi, Milad Behboudi, Emad Soltani, Saber Int J Infect Dis Article The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-26 /pmc/articles/PMC8312046/ /pubmed/34325045 http://dx.doi.org/10.1016/j.ijid.2021.07.053 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zandi, Milad
Behboudi, Emad
Soltani, Saber
Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title_full Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title_fullStr Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title_full_unstemmed Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title_short Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
title_sort letter to the editor: can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the sars-cov-2 proteins?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312046/
https://www.ncbi.nlm.nih.gov/pubmed/34325045
http://dx.doi.org/10.1016/j.ijid.2021.07.053
work_keys_str_mv AT zandimilad lettertotheeditorcantheseasonalinfluenzavaccinefor20192020havecrossreactivitywithsomeofthesarscov2proteins
AT behboudiemad lettertotheeditorcantheseasonalinfluenzavaccinefor20192020havecrossreactivitywithsomeofthesarscov2proteins
AT soltanisaber lettertotheeditorcantheseasonalinfluenzavaccinefor20192020havecrossreactivitywithsomeofthesarscov2proteins

Ejemplares similares